Can adding surgery or radiation to a targeted pill slow lung cancer better?
NCT ID NCT03410043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus local treatments. The goal is to see if the combination improves cancer control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
University of Colorado
Denver, Colorado, 80217-3364, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy